← All indications
Vitiligo
A disorder consisting of areas of macular depigmentation, commonly on extensor aspects of extremities, on the face or neck, and in skin folds. Age of onset is often in young adulthood and the condition tends to progress gradually with lesions enlarging and extending until a quiescent state is reached.
Drugs by status
Approved for this indication (2)
Phase 4 trials (14)
Phase 3 trials (12)
Phase 2 trials (24)
Phase 1 trials (10)
Organizations
Organization Involved with Phase 4 Indications (9)
Organization Involved with Phase 3 Indications (9)
Organization Involved with Phase 2 Indications (20)
- Aclaris Therapeutics, Inc.
- Celgene
- Amgen
- Pfizer
- Novartis
- Clinuvel Pharmaceuticals Limited
- National Institute of Allergy and Infectious Diseases (NIAID)
- National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS)
- Centro Studi Gised
- Tufts University
- University of Medicine and Dentistry of New Jersey
- Yale University
- University of British Columbia
- University of Colorado, Denver
- Icahn School of Medicine at Mount Sinai
- Nicolaus Copernicus University
- San Gallicano Dermatological Institute, Roma
- University of Massachusetts
- Roivant Sciences, Inc.
- ARIV Onlus
Organization Involved with Phase 1 Indications (10)
Organization Involved with Other Experimental Indications (11)